Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CEA cell adhesion molecule 6 (CEACAM6)
- Target
- CEACAM6
- Molecular classification
- Cell adhesion molecule, GPI-anchored membrane glycoprotein, Immunoglobulin superfamily, Other (Carcinoembryonic antigen-related molecule)
01
Overview
CEA cell adhesion molecule 6 (CEACAM6) is a glycosylphosphatidylinositol (GPI)-anchored cell surface glycoprotein and a member of the carcinoembryonic antigen (CEA) family, predominantly involved in intercellular adhesion, tumor cell migration, immune modulation, and is overexpressed in a variety of cancers. It mediates cell-cell and cell-matrix interactions, impacts tumor proliferation, invasion, metastasis, and chemoresistance, and is under investigation as a target for antibody- and cell-based cancer therapies. It also plays roles in neutrophil adhesion and hosts as a receptor for bacterial adhesion (notably in Crohn’s disease)
- Other names
- CD66cNCANCA-50/90non-specific cross-reacting antigenCEAL
02
Mechanism of action
Monoclonal antibodies and CAR-T cells targeting CEACAM6 aim to induce tumor cell death via immune-mediated processes or to block CEACAM6-mediated cell adhesion and downstream signaling pathways (e.g., ERK1/2/MAPK, SRC/FAK/PI3K/AKT)
03
Biological functions
Cell adhesionCell signalingImmune modulationTumor progressionCell migration and invasion
04
Disease associations
Cancer (multiple types including pancreatic, colorectal, lung, breast, and gallbladder)Inflammation (notably Crohn’s disease)
05
Safety considerations
On-target off-tumor effects due to expression of CEACAM6 in some normal tissues (especially gastrointestinal and respiratory epithelium)Potential immune-related adverse events in CEACAM6-directed immunotherapies
06
Interacting drugs
No major approved drugs, but investigational monoclonal antibodies and CAR-T therapies are under preclinical and clinical development targeting CEACAM6 in cancer
07
Biomarkers
CEACAM6 expression is used as a prognostic and diagnostic biomarker in several cancers (notably pancreatic ductal adenocarcinoma, gastrointestinal and colorectal cancers)
Beyond the preview
Go deeper on CEA cell adhesion molecule 6 (CEACAM6).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CEA cell adhesion molecule 6 (CEACAM6).